Expanded Access and Expedited Approval
of New Therapies Related to HIV/AIDS
FDA has taken several significant steps primarily in response to the HIV/AIDS crises,
toward making experimental drugs intended to treat life-threatening diseases more widely
available to severely ill patients, as well as toward speeding up the review and approval
of the applications for these products.
Expedited Procedures
- In 1987, FDA created a "AA" priority category to classify all applications for
potential AIDS therapies to ensure that these products receive the highest priority in the
review process.
- In October, 1988, FDA issued interim regulations designed to expedite marketing approval
of new drugs intended for life-threatening and severely-debilitating diseases, by
facilitating the clinical testing and evaluation process. Under the expedited procedures,
early consultation with FDA by drug manufacturers, with agreement on the proper design of
clinical trials, can lead to phase 2 studies with adequate data to support approval. In
some instances, the need for Phase 3 testing can be virtually eliminated.
- On December 11, 1992, FDA published the final rule to accelerate the approval of new
drugs for serious and life-threatening diseases when the drug provides meaningful
therapeutic benefit over existing products. Under these procedures FDA may approve drugs
based on surrogate endpoints that reasonably predict that a drug provides clinical
benefit. This clinical benefit is then confirmed through additional human studies that
will be completed after marketing approval. The accelerated approval approach provides for
removal of the drug from the market if further studies do not confirm the clinical benefit
of the therapy.
- On December 12, 1995, FDA published a report, "Timely Access to New Drugs in the
1990s: An International Comparison," which documents FDA's tough standards do not
delay consumer access to important new dugs, compared to other countries and that the
United States has available valuable drugs as soon as, and in many cases sooner than, its
counterparts around the world. Six antivirals have received approval for the treatment of
HIV: two were approved in three months, three in six months and one in eight-and-a-half
months.
Antiretrovirals Currently Approved
For HIV Infection and AIDS-related Conditions
Product |
Approval |
Review Time to Approval |
Retrovir (AZT) |
March 1987 |
3.5 months |
Videx (ddI) |
October 1991 |
6 months |
Hivid (ddC) |
June 1992 |
6 months |
Zerit (d4T) |
June 1994 |
6 months |
Epivir (3TC) |
November 1995 |
6 months |
Invirase (saquinavir) |
December 1995 |
3 months |
Norvir (Ritonavir) |
March 1996 |
2.5 months |
Crixivan (Indinavir) |
March 1996 |
1.5 months |
Viramune (nevirapine) |
June 1996 |
4 months |
Viracept (nefinavir) |
March 1997 |
2.8 months |
Rescriptor (delavirdine) |
April 1997 |
8.8 months |
Combivir (AZT &
lamivudine) |
September 1997 |
4 months |
Fortovase (saquinavir
soft gelatin capsule) |
November 1997 |
6 months |
Expanded Access Mechanisms
- Expanded access mechanisms are designed to make promising products available as early in
the drug evaluation process as possible.
- Expanded access mechanisms include Treatment IND protocols and parallel track protocols.
In addition, the ordinary development of drugs under an IND includes a variety of open
studies that also provide access to drugs. FDA monitors each of these access programs on
an ongoing basis.
Examples of Expanded Access Enrollment
Drug |
Dates |
# Enrolled |
AZT |
1986-87 |
4,804 |
trimetrexate |
1988-94 |
753 |
pentamidine |
1989 |
728 |
ddI |
1989-91 |
>21,000 |
ddC |
1990-92 |
6,705 |
atovaquone |
1991-93 |
1,054 |
rifabutin |
1992-93 |
2,506 |
d4T |
1992-94 |
12,551 |
3TC |
1993-95 |
29,430 |
saquinavir |
1995 |
2,200 |
indinavir |
1995 |
1,500 |
Treatment INDs
- Final regulations were issued in May of 1987 establishing conditions under which
promising new drugs and biologics that have not yet been approved or licensed may be made
available to persons with serious and life threatening illnesses. Treatment INDs have
generally been granted when the product is well into clinical trials or when all clinical
trials have been completed, after the development of some reliable evidence that the
product is effective.
- Eleven treatment IND protocols for promising AIDS-related products have been allowed to
proceed since the Treatment IND regulations became effective.
Parallel Track
- The final PHS policy statement on the parallel track mechanism was published in the
Federal Register on April 15, 1992. The purpose of the parallel track policy is to expand
the availability of promising investigational drugs to those persons with AIDS and
HIV-related diseases who are without satisfactory alternative therapy and who cannot
participate in controlled clinical trials.
- Stavudine (d4T) has been the only drug submitted for consideration under the parallel
track policy. The protocol was allowed to proceed on October 5, 1992. Approximately 12,000
patients received Stavudine through the parallel track mechanism. An accelerated new drug
application for stavudine was approved June 17, 1994. The application received full
marketing approval on December 21, 1995.
- FDA is responsible for assuring that the availability of a drug under the parallel track
program does not interfere with the drug sponsor's ability to carry out well-controlled
studies on the drug and does not encourage patients with other approved treatment
alternatives to resort to untested investigational drugs.
Last revised March 5, 1998, Office of Special Health Issues, HF-12